MYC and Miyoshi myopathy: Interestingly, the antiproliferative effect induced by combination treatment occurred together with a strong downregulation of MYC in MM cells, thus confirming the relevance of MYC downregulation as a potential mediator of miR-22/lenalidomide combinatorial activity on MM cell viability (Figure 6b, right).